Browsing by Author "Wabinga, H."

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Hepatitis B virus and HIV infection among patients with primary hepatocellular carcinoma in Kampala, Uganda
    (African health sciences, 2011) Ocama, P.; Opio, K. C.; Kagimu, M.; Seremba, E.; Wabinga, H.; Colebunders, R.
    Hepatitis B virus (HBV) is the commonest cause of primary hepatocellular (PHC) carcinoma worldwide. Coinfection with the HIV leads to more rapid progression of liver disease. Objectives: We described prevalence of HBV and HIV among patients with PHC admitted to Mulago Hospital, Kampala, Uganda. Methods: We assessed all patients admitted to the gastrointestinal service of Mulago hospital with a diagnosis of PHC for HBV and HIV infection. Results: From March to June 2008, we recruited 15 patients. Nine (60%) were male; the overall median age was 32 years (IQR 15 -67), with median ages for male and female 33 and 36 years respectively. Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and AFP were all elevated with median values of 57.5 IU/L, 222 IU/L, 392 IU/L and 362 ng/ml respectively (IQR 14-145, 49-393, 165-1294 and 7-480). Eight (53%) patients were from North and Northeastern Uganda. The HBsAg was reactive in 13(87%) patients and HIV in 3(20%), all of whom were also co-infected with HBV. Conclusion: There is high prevalence of HBV and HBV/HIV co-infection among patients with PHC in Uganda with high mortality. Reduction in incidence and mortality due to PHC in Uganda will require urgent large scale HBV vaccination.
  • Thumbnail Image
    Item
    Myelodysplasia in Ugandan Patients with HIV/AIDS: An Autopsy Study
    (East African Medical Journal, 2011) Nabadda, S.; Odida, M.; Wabinga, H.
    Myelodysplasia has been reported to occur quite frequently in the spectrum of HIV/AIDS disease and is thought to be partly responsible for bone marrow failure in these patients. However, the frequency and type of myelodysplasia appear to differ at different stages of the disease in different populations with mechanisms of its development not well understood.
  • Thumbnail Image
    Item
    Planning for future Cancer Control Programs in Uganda: Projections of top five Cancers’ Incidence in the next Decade
    (Annals of Oncology, 2019) Asasira, J.; Mai, T.X.; Wabinga, H.; Chang, Y.; Cho, H.
    Projections of the national burden of cancer are essential for planning cancer control programs and anticipating future cancer burden on the health service. This study aims to evaluate the current trend and project cancer incidences of the top five cancers in Uganda: Kaposi sarcoma (KS), cervical, breast, prostate, and Non-Hodgkin’s lymphoma (NHL). Projections were based on incidence data obtained from the population-based Kampala cancer registry for the 2000-2014 periods, and population data was acquired from the National Bureau of Statistics. Joinpoint software was used to study the trend and presented results using age-specific rates, age-standardized rates, crude rates, and annual percentage change. Two methods were applied to project incidence up to 2029. First, we extrapolated results of the recent trend from joinpoint model to estimate future incidence with the assumption that coefficient estimates will remain constant. Second, we fitted the age-period-cohort model using Nordpred R-package, which accounts for age, period-birth cohort effects, rates were standardized using the standard world population (WHO 2000-2025). Breast, cervical, and prostate cancer incidences are forecasted to increase by 2029. Their new cases are expected to increase by 200.5%, 98.7% and 184.3 % respectively with the ASRs (per 100,000) escalating from 30.9, 51.9, 44.9 in 2000-2004 to 40.8, 52.7, 64.3 in 2025-2029. Incidences of KS and NHL are, on the other hand, anticipated to decrease for both males and females with both projection methods showing the same results. From 2000 to 2029, the ASR is expected to decrease markedly from 30.3 to 6.1 for KS and from 7.3 to 2.4 for NHL. The reduction in the number of cases is predominantly attributed to the change in their risk. The incidence rates were at peak among people aged from 65 to 74 for breast, cervical, prostate cancers, and those above 75 years for KS and NHL in the observed period. These patterns are expected to remain unchanged in the next decade. Future research should be directed towards strategies to control the growing burden of breast, cervical, and prostate cancers since their incidence rates are forecasted to increase in the future according to our study.